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Abstract
Background: Human papillomavirus (HPV) is the carcinogen of almost all invasive cervical cancer and a major
cause of oral and other anogenital malignancies. HPV genotyping by dideoxy (Sanger) sequencing is currently the
reference method of choice for clinical diagnostics. However, for samples with multiple HPV infections, genotype
identification is singular and occasionally imprecise or indeterminable due to overlapping chromatograms. Our aim
was to explore and compare HPV metagenomes in abnormal cervical cytology by deep sequencing for correlation
with disease states.
Results: Low- and high-grade intraepithelial lesion (LSIL and HSIL) cytology samples were DNA extracted for PCR-
amplification of the HPV E6/E7 genes. HPV+ samples were sequenced by dideoxy and deep methods. Deep sequencing
revealed ~60% of all samples (n = 72) were multi-HPV infected. Among LSIL samples (n = 43), 27 different genotypes were
found. The 3 dominant (most abundant) genotypes were: HPV-39, 11/43 (26%); -16, 9/43 (21%); and -35, 4/43 (9%).
Among HSIL (n = 29), 17 HPV genotypes were identified; the 3 dominant genotypes were: HPV-16, 21/29 (72%); -35, 4/29
(14%); and -39, 3/29 (10%). Phylogenetically, type-specific E6/E7 genetic distances correlated with carcinogenic potential.
Species diversity analysis between LSIL and HSIL revealed loss of HPV diversity and domination by HPV-16 in HSIL
samples.
Conclusions: Deep sequencing resolves HPV genotype composition within multi-infected cervical cytology. Biodiversity
analysis reveals loss of diversity and gain of dominance by carcinogenic genotypes in high-grade cytology. Metagenomic
profiles may therefore serve as a biomarker of disease severity and a population surveillance tool for emerging genotypes.
Keywords: Human papillomavirus, HPV genotyping, High-throughput sequencing, Deep sequencing, Metagenome,
Virome, LSIL, HSIL
Background
The first description of cervical cancer was documented
by Hippocrates c. 450 BCE [1]. Its cause remained a mys-
tery for two millennia until 1983 when zur Hausen and
colleagues isolated and cloned HPV-16 from cervical car-
cinoma [2]. HPV is now recognized as the carcinogen of
almost all invasive cervical cancer and a major cause of
other human malignancies including vulvovaginal, oro-
pharyngeal, penile, and anal cancers [3, 4].
The HPV genome is a ~8,000 base pair (bp), double-
stranded, circular DNA. The prototypical genome en-
codes 6 early genes (E1, E2, E4, E5, E6, and E7) and 2
late genes (L1 and L2) [5]. By convention, HPV classifi-
cation is based on the L1 gene where a difference of
>10% in the viral sequence defines a different genotype
[6]. With the advent of sequencing technologies, the list
of papillomavirus (PV) genotypes has grown to 333 with
202 types isolated from humans and 131 from animals
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[7]. The conferment of HPV oncogenic potential is de-
rived from two viral oncoproteins E6 and E7, which in-
activate two primary cellular proteins: p53 and RB,
respectively [5, 8, 9]. Inhibition followed by degradation
of p53 and RB leads to cell-cycle progression,
immortalization, and malignant transformation of the
HPV-infected cell [5]. The E6 and E7 proteins of
carcinogenic HPV possess a structural advantage,
namely, conformational plasticity that may be respon-
sible for multi-target binding and transformation in host
cells [9, 10]. Hence, sequencing the E6/E7 genes to de-
code its oncogenic potential through association with
known genotypes by genetic proximity may be a pre-
ferred diagnostic test.
Sanger sequencing of PCR amplicons is accurate in the
detection of single HPV infections and yields easily inter-
pretable data [11]. For samples with multiple HPV infec-
tions, genotype identification may be imprecise or
indeterminable because of noisy (overlapping signals)
chromatograms causing failures in nucleotide alignment
[11]. Furthermore, non-dominant genotypes in mixed in-
fections may not be detected by the Sanger method and
may be consequently underestimated. Therefore, to prop-
erly identify all HPV types in a complex sample, contem-
porary next-generation sequencing (NGS), also referred to
as deep or high-throughput sequencing (HTS), may pro-
vide an innovative solution [12]. Although the literature is
limited, several NGS platforms have been successful at de-
termining the diversity of HPV genotypes found in human
skin, normal cervical cytology, and cytology of an HIV+
woman harboring 16 types [13–16].
In this study, we aimed to determine the HPV genotypes
and their proportional composition in single- and multi-
infected cervical samples. Specifically, two categories of
cytology, i.e. low- and high-grade squamous intraepithelial
lesion (LSIL and HSIL) containing HPV DNA were
selected for deep (Illumina®) sequencing to explore viral
diversity and characterize differences in metagenomes.
Methods
Subjects and samples
This study was conducted after approval by the Institu-
tional Review Board of Brooke Army Medical Center
(BAMC), Texas. Liquid-based cytology collected for clin-
ical testing at the Department of Pathology was consecu-
tively procured after completion of analysis for cytological
diagnosis. Demographic data were abstracted from the
electronic health record (AHLTA) of the Department of
Defense (DoD) and linked to each specimen. Similarly,
histologic data were abstracted for cytohistological correl-
ation. In a previous study, three categories of samples, i.e.
negative for intraepithelial lesion or malignancy (NILM),
LSIL and HSIL were collected for HPV genotyping and
DNA methylation analysis [17]. For this study, we selected
only the subset of HPV+ LSIL (n = 55) and HSIL (n = 29)
for characterization and comparison of viral diversity be-
cause of the high prevalence of HPV positivity.
HPV DNA amplification and detection
Cervical cytology (10 mL) was centrifuged (4,000 rpm x
2 min), and the supernatant was removed (laboratory
schema shown in Fig. 1a). The cell pellet (200–250 uL)
was transferred into sample tubes for DNA extraction
using the QIAamp DNA Mini kit on the QIAcube robot
(QIAGEN). The purified DNA in 150 uL of eluent was
quantified by spectrophotometry and stored at -20 °C. For
HPV DNA amplification, the consensus primer set: GP-
E6-3 F/GP-E7-5B/GP-E7-6B was used to amplify a region
of E6/E7 genes for genotype identification [18, 19]. The
Multiplex PCR Plus kit (QIAGEN) was used with the trip-
let primer set per manufacturer’s instructions. Briefly,
PCRs were performed in a final volume (50 uL) containing
template DNA (200 ng), PCR master mix (25 uL), forward
and reverse primers (1uM each, final concentration), and
RNAase-free water. The cycling protocol was as follows:
activation [95 °C x 5 min]; 45 cycles [94 °C x 30 s, 55 °C x
90 s, 72 °C x 90 s]; final extension [72 °C x 10 min]. After
PCR, high-resolution capillary gel electrophoresis was
used to detect amplicons by the QIAxcel (QIAGEN) with
a detection sensitivity of 0.1 ng/μL and DNA resolution of
3–5 bp. Samples with ≥1 amplicon were sequenced.
HPV DNA dideoxy (Sanger) sequencing and genotyping
PCR products were purified using the GeneRead Size Se-
lection Kit (QIAGEN) and eluted in 100 uL of molecular
biology-grade water on the QIAcube. Dideoxy sequencing
of the amplicons (~200 ng DNA/sample) was performed
using primer GP-E6-3 F at Eurofins Operon (USA).
Sequence quality was assessed using Sequence Scanner
2.0 (appliedbiosystems.com) where a “high quality” Trace
Score (TS) was defined as ≥20 and a QV20+ value (total
number of bases in the sequence with TS ≥20) as ≥100.
Quality sequences were entered into BLAST® and queried
against HPV sequences in GenBank® (Taxon identifier:
151340) for genotyping as previously described [11].
HPV DNA sample library preparation and deep
sequencing
DNA libraries were prepared from GeneRead-purified PCR
products as described above using the Nextera XT kit (Illu-
mina). Briefly, the input DNA was quantitated and analyzed
for purity (260/280 nm absorbance ratio ~1.8-2.0) with the
Qubit Fluorometer (ThermoFischer). Each DNA sample
(1 ng) with a standardized concentration of 0.1-0.2 ng/uL
was “tagmented” (fragmented and tagged with sequencing
adapters) by the Nextera XT transposome and dual indexed
(barcoded) by limited-cycle PCR using the 96-sample Nex-
tera Index Kit. AMPure magnetic beads (Beckman Coulter)
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were used to purify the DNA libraries and size select (300–
500 bp) amplicons in each sample. The DNA libraries were
normalized for quantity to ensure equal representation
from each sample prior to pooling and sequencing. Paired-
end bi-directional sequencing (2 × 300 bp) using the MiSeq
Reagent Kit v3 (600-cycle) was performed on the MiSeq
(Illumina) for bridge amplification.
Bioinformatics for next-generation genotyping
The MiSeq on-instrument analysis generated a QC re-
port of total reads, total reads passing filter, and % of
bases with quality score ≥30 (Q30) meaning an accuracy
rate of 99.9% [20]. The de-multiplexed, paired-end se-
quences were imported into CLC Genomics Workbench
8.0 (QIAGEN) for analysis. The bioinformatics workflow
Fig. 1 Protocol schema and bioinformatics workflow. a Residual liquid-based cervical cytology collected for DNA extraction, PCR amplification of HPV
DNA, and amplicon detection by capillary electrophoresis. Samples with + HPV DNA were sequenced by dideoxy (Sanger) and deep sequencing
(Illumina®) methods for genotype identification. b Bioinformatics workflow created for next-generation sequencing (NGS) data and BLAST® search for
HPV genotyping. Workflow layout in CLC Genomics Workbench consisting of 5 sequential steps: reads import, reads merging, reads QC, de novo
assembly with mapping, and NCBI BLAST® search. c Representative read mapping result. Top to bottom: consensus sequence with nucleotide color
space encoding (colored dots), coverage level (pink-bar height), and sequence reads (forward: green; reverse: red). d Representative nucleotide BLAST®
result. The top sequence is the input (query) sequence, e.g., a consensus sequence derived from de novo assembly with nucleotide encoding (colored
dots). Below, the matched (hit) sequences are displayed with nucleotide coloring and GenBank ID on the left. BLAST, Basic Local Alignment Search
Tool; NCBI, National Center for Biotechnology Information; QC, Quality Control
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constructed for HPV genotyping consisted of 5 sequen-
tial steps: reads import, reads merging, reads QC, de
novo assembly with mapping, and BLAST® search
(Fig. 1b). A read mapping result following de novo assem-
bly produced contigs and the consensus sequence (Fig. 1c).
Only consensus sequences with contigs composed of ≥100
reads from each sample were BLAST® (blastn) searched
against the NCBI Viral Genome database. BLAST® hit re-
sults (Fig. 1d) were used for HPV genotype assignment
[11]. Of note, the minimum coverage and percentage of
reads required for accurate HPV genotype identification
has not been reported to date. For this study, the mini-
mum coverage (100x) for variant detection was based on
the manufacturer’s technical note on coverage require-
ment for reads mapped to a subset of a genome [21]. The
CLC Genomics workflow parameter settings are presented
in Additional File 1: Table S1.
Species diversity and phylogenetic analysis
The term species in biodiversity analysis refers to a sam-
pling unit under study. Herein, the sample unit is the
HPV genotype rather than species. HPV community is de-
fined as the assemblage of different genotypes found in
each sample by deep sequencing and grouped as LSIL or
HSIL for comparative analysis. Count-based genotype di-
versity and dominance within a HPV community were
quantified by the Shannon-Wiener Index (SWI) and
Berger-Parker Index (BPI), respectively and compared
using Solow’s randomization test [22]. Composition-based
genotype dissimilarity between communities (β-diversity)
was calculated using the Analysis of Similarity (ANOSIM)
method based on percentage differences between samples
[23, 24]. ANOSIM is a non-parametric statistical test for
significant differences in species composition (%) between
two or more groups/sites of sampling units. The ANOSIM
statistic R compares the mean ranks of species similarities
between and within groups [24]. Principal component
analysis (PCA) was used to determine the most influential
variables (HPV types) in the LSIL or HSIL group. PCA
was performed on the covariance matrix of natural log-
transformed abundance data [ln(x + 1)] of HPV-types
within each sample [24, 25]. Log transformation was ap-
plied to reduce the influence of highly abundant genotypes
(skewed data). Biodiversity analyses were performed using
Species Diversity and Richness 4.0 and Community Ana-
lysis Package 5.0. [22, 24]
The evolutionary relationship of HPV E6/E7 from deep
sequencing of LSIL and HSIL samples was inferred using
the Neighbor-Joining method [26]. The evolutionary dis-
tances were computed using the Maximum Composite
Likelihood method [27]. Codon positions included were
1st + 2nd + 3rd +Noncoding. Positions containing gaps or
missing data were eliminated. Bootstrap analysis using
1,000 replicates was performed to evaluate the reliability
of the inferred trees [28]. The bootstrap value attached to
each node is the confidence (%) in the subtree rooted at
the node. Evolutionary analyses were conducted in
MEGA6 [29].
Definitions
The classification of HPV carcinogenic potential was
based on the World Health Organization (WHO) Inter-
national Agency for Research on Cancer (IARC) Work-
ing Group Reports [8, 30]. Specifically, HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 were
deemed carcinogenic; HPV types 26, 30, 34, 53, 66, 67,
69, 70, 73, 82, 85, and 97 were possibly carcinogenic;
HPV types 6, 11 were not classifiable; and all others
were probably not carcinogenic. The not classifiable
agents are generally considered not carcinogenic based on
limited epidemiological and experimental data. The ra-
tionale for categorizing HPV 6 as not classifiable instead
of probably not carcinogenic was the low (0.45% [95% CI:
0.35-0.56]) but not zero incidence found in invasive cer-
vical cancers worldwide [30]. It is postulated that HPV-6
and other low-risk genotypes may rarely cause cancer due
to unusual “virus-host circumstances” [30]. Therefore, the
not classifiable/probably not carcinogenic genotypes are
generally considered non-carcinogenic and thus grouped
together for this study. The probably not carcinogenic
group include HPV species alpha-1, -2, -3, -4, -8, -10
(other than HPV 6, 11), -13, -14/15 [8, 30].
Statistical analysis
Data were summarized using means (95% CI), medians
(IQR), and proportions. Normality of data distribution was
determined by the skewness and kurtosis test. For non-
parametric data, the median test (Fisher’s exact, 2-tailed) or
chi-squared test were used for hypothesis testing as appro-
priate. Agreement between 2 dichotomous categorical vari-
ables was calculated using simple agreement (%) and kappa
coefficient. Kappa coefficients are categorized by the follow-
ing nomenclature: poor (κ < 0.00); slight (0.00 ≤ κ ≤ 0.20);
fair (0.21 ≤ κ ≤ 0.40); moderate (0.41 ≤ κ ≤ 0.60); substantial
(0.61 ≤ κ ≤ 0.80); and almost perfect (κ > 0.80) [31]. A p-
value <0.05 was considered statistically significant. Statis-
tical analyses were performed using STATA/IC 13.0 (Stata-
Corp, Texas).
Results
Mixed HPV infections are frequent and unresolved by
dideoxy (Sanger) sequencing
A total of 84 cytology samples were collected for this
study. Twelve LSIL samples were excluded because of
technical failure in the deep sequencing assay. Hence 72
samples categorized as LSIL (n = 43) and HSIL (n = 29)
were analyzed and reported herein. The demographic
distribution of the subjects (n = 72) whose cytological
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samples underwent study were as follows: White (43%),
Black (11%), Asian (3%), other (22%), and unknown (21%).
The median age of the cohort was 26 years (IQR, 23-33).
For the HSIL group, the median age (28 years [IQR, 24-
33]) was greater than that of the LSIL group (24 years
[IQR, 23-31]) (median test, p = 0.02) (age distribution
shown in Additional File 2: Figure S1). Histologic valid-
ation of the cytology samples showed overall good agree-
ment (78%) (κ = 0.6, p <0.001) as summarized in Table 1.
The median concentration of extracted cellular DNAs
was 43.5 ng/uL (IQR, 35.2-69.0). All DNA samples
underwent PCR amplification of the HPV E6/E7 loci
that yielded the expected 660-bp fragments on electro-
phoresis. Samples with single or multiple HPV infections
displayed corresponding numbers of amplicon bands
with detectable variations in base-pair size because of
genotype-specific differences in the E6/E7 fragments
(Fig. 2a). Multiple amplicons were detected in 25% (18/
72) of specimens, with similar contributions from LSIL
(12/43, 28%) and HSIL (6/29, 21%) (χ2, p = 0.50). Down-
stream dideoxy sequencing of these amplicons revealed
“clean” and “overlapping” patterns on the chromatogram
indicative of pure and mixed E6/E7 sequences, respect-
ively (Fig. 2b). Only the dominant HPV genotype within
each sample that is resolvable by dideoxy sequencing is
presented in Additional File 3: Table S2. These results
were used for validation of genotyping by deep sequen-
cing as described below.
Deep sequencing of HPV E6/E7 loci reveals loss of HPV
diversity and gain of clonal dominance in HSIL
The deep sequencing read statistics of all samples are
summarized in Table 1. The total number of passed-
filtered reads was 21 million, which is consistent with the
maximum number of reads (25 million) for the MiSeq
Reagent Kit used. The median number of merged reads
for 72 samples derived from E6/E7 loci amplification was
242,665 (IQR, 185,144-324,210), and the proportion of
mapped to merged reads was 79% (192,236/242,665). The
number of mapped reads per sample was sufficient to dis-
cover up to 8 genotypes. The HPV genotypes based on
BLAST® are listed in Additional File 3: Table S2.
Figure 3 illustrates the HPV community found in LSIL
and HSIL according to genotype and carcinogenicity.
For LSIL E6/E7–amplicons (n = 43), deep sequencing
identified the number of genotype(s)/sample as: 1(40%),
2 (26%), 3(21%), and ≥4 (14%). A total of 27 different ge-
notypes were found in single and multi-infected samples.
The dominant (most abundant) genotype in LSIL sam-
ples included: HPV-39, 11/43 (26%); -16, 9/43 (21%);
and -35, 4/43 (9%). For HSIL E6/E7–amplicons (n = 29),
deep sequencing identified the number of genotype(s)/
sample as: 1(38%), 2(28%), 3(10%), and ≥4 (24%). Over-
all, 17 HPV different genotypes were identified in all
HSIL samples. The dominant genotype in HSIL samples
included: HPV-16, 21/29 (72%); -35, 4/29 (14%); and -39,
3/29 (10%). All dominant HPV genotypes found in HSIL
were carcinogenic (29/29, 100%). In addition, the median
age of the subjects who had a dominant, carcinogenic
HPV genotype (26 years [IQR, 23–31]) versus all other
IARC-defined categories (25.5 years [IQR, 24–38]) was
not statistically different (median test, p = 0.77) (age distri-
bution shown in Additional File 4: Figure S2).
HPV genotype diversity analysis (shown in Fig. 4a)
based on the Shannon-Wiener Index (SWI) revealed a
significant loss of genotype diversity from LSIL (SWI,
3.01) to HSIL (SWI, 2.28) (p <0.001) and domination by
HPV-16 in HSIL (BPI = 0.34) (p <0.001). Diversity
between HPV communities of LSIL and HSIL varied sig-
nificantly (ANOSIM R = 0.07, p <0.05). We determined
the three most influential HPV genotypes (-16, -35, -39)
in the mixed compositions of LSIL and HSIL samples by
PCA (Fig. 4b). Among these, species dissimilarity ana-
lysis determined a greater average abundance of HPV-16
(68%) and -35 (13%) in HSIL; in contrast, HPV-39 (24%)
was more abundant in LSIL.
Validation of our next-generation genotyping results
showed high concordance between the deep and dideoxy
sequencing methods. Comparing the dominant HPV ge-
notypes derived from the two methods, the inter-assay
agreement was highly concordant for LSIL (κ = 0.91, p
<0.001) and HSIL (κ = 0.85, p <0.001) (Table 1). This find-
ing indicates that dideoxy sequencing may be used to de-
termine the dominant genotype within mixed infections.
Evolutionary relationship of HPV E6/E7 sequences
correlate with carcinogenic potential
A neighbor joining tree was constructed from 160 E6/E7
sequences derived from single and mixed infections of 72
LSIL/HSIL samples (full tree shown in Additional file 5:
Figure S3). A representative tree constructed from 28 E6/
E7 sequences (one from each genotype) is presented in
Fig. 5. The aligned E6/E7 sequences grouped likewise to
L1-based phylogenetic trees [8, 30]. Moreover, the genetic
distances or evolutionary divergences between the species
correlated with IARC-defined carcinogenicity [8, 30].
Taken together, the genetic sequence of E6/E7 alone was
sufficient to genotype and phenotype (carcinogenicity) the
samples. Another observation is the non-detectable differ-
ence between E6/E7 branch lengths for LSIL and HSIL
among individual genotypes. This finding suggests that
disease severity was not associated with HPV-subtype
differences (2–10% nucleotide differences) [6].
Discussion
This study revealed the complex HPV communities resid-
ing in abnormal cervical cytology. We found that patients
with LSIL and HSIL are frequently (~60%) infected with
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multiple HPV genotypes. Deep amplicon sequencing gener-
ated abundant mapped reads and deciphered the compos-
ition of genotypes within each sample. The total number of
HPV types identified by sequencing single and multi-
infected samples ranged from 27 for LSIL to 17 for HSIL
and spanned the spectrum of IARC-defined carcinogenicity
[8, 30]. More specifically, the viral community differed be-
tween LSIL and HSIL with a loss of genotypic diversity and
domination by carcinogenic HPVs, in particular, HPV-16 in
HSIL. The inverse correlation between HPV diversity and
progressive disease is consistent with the findings of 1,518
cervical biopsies ranging from CIN 0 to 3 in the ATHENA
Table 1 Cytohistological correlation and HPV E6/E7 deep sequencing results
Cytohistological Correlation
Histology Total LSIL HSIL
Samples, n 72 43 29
Histology (biopsy or excision)a
Documented, n (%) 51 (71) 26 (60) 25 (86)
Not documented, n (%) 21(29) 17(40) 4(14)
Histological Gradea
CIN 0, n (%) 4 (8) 4 (15) 0
CIN I, n (%) 23 (45) 19 (73) 4 (14)
CIN II/III, n (%) 24 (47) 3 (12) 21 (84)
Cytohistological agreementb
Agreement, % 78




Deep Sequencing Reads for LSIL/HSIL
Mergedc Mappedd
Read Statistic Total Total HPV#1 HPV#2 HPV#3 HPV#4 HPV#5 HPV#6 HPV#7 HPV#8
Samples, n 72 72 72 44 25 13 8 5 2 1
Median, n 242,665 192,236 178,582 14,483 4,040 2,480 2,403 578 590 304
Minimum, n 11,174 6,022 6,022 367 135 407 412 366 332 -
Maximum, n 760,725 673,342 656,806 147,734 62,768 36,970 4,910 3,356 847 -
25th %tile, n 185,144 155,214 99,651 3,535 1,021 566 729 379 332 -
75th %tile, n 324,210 269,603 243,612 45,484 13,102 6,712 3,717 1,634 847 -
HPV Genotype Concordance Analysis
Deep vs. Sanger sequencinge
Agreement Statistic LSIL HSIL
Samples, n 43 29
Agreement, % 93 93
Expected Agreement, % 13 53
Kappa 0.92 0.85
Std. Error 0.054 0.119
p-value <0.001 <0.001
CIN cervical intraepithelial neoplasia, E6/E7 HPV E6/E7 gene amplified by PCR, HSIL high-grade squamous intraepithelial lesion, HPV human papillomavirus, LSIL
low-grade squamous intraepithelial lesion
aCervical histopathology is based on the highest grade documented on cervical biopsy or therapeutic excisional biopsy, i.e. cold knife conization (CKC) and loop
excisional procedure (LEEP). Absence or presence of pathology reports in the DoD electronic health records was categorized as “Documented” or “Not
documented,” respectively
bCytohistological agreement was calculated using samples with documented histopathology
cThe total number of passed filtered reads was 21 million and merged reads was 18 million
dThe mapped reads corresponding to the nth HPV genotype(s) found in LSIL and HSIL samples is listed in descending order
eThe dominant (most abundant) HPV genotype determined by BLAST alignment of deep and dideoxy sequences were paired for concordance analysis
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(Addressing The Need for Advanced HPV diagnostics) trial
[32]. Furthermore, carcinogenic HPVs, in particular HPV-
16 and -18, have been shown to be indicators and predic-
tors of CIN 3 development [32, 33]. Carcinogenic HPV
dominance (≥50%) may also be an indicator of underlying
high-grade disease, as found in 12% (3/26) of LSIL
upgraded to CIN 2/3 on biopsy. Together, these metage-
nomic characteristics are consistent with the ecological
principles of competitive exclusion and carcinogenesis hall-
marked by clonal expansion and evolution of transformed
cells as illustrated in Fig. 6 [34–40]. The distinguishing fea-
tures of altered diversity and dominance between HPV
communities may serve well as a biomarker for disease se-
verity. The addition of evolutionary analysis to sample E6/
E7 sequences assists in determining carcinogenic potential
based on genetic distances to HPV reference sequences. In
this way, deep sequencing revealed the dynamic ecology of
HPV coexisting and evolving within the cervical epithelium,
a characteristic that would otherwise remain unseen by
traditional sequencing.
Currently, published data on deep sequencing of HPV
in abnormal cytology are limited and varied. Previous
studies have analyzed target (non-generalizable) popula-
tions, used different NGS platforms and assays, and re-
ported findings that may not be translatable between
platforms [13–16, 41]. However, we did find several not-
able similarities. A metagenomics study of healthy per-
sons from the NIH Human Microbiome Project revealed
a high prevalence of HPV in the vagina (41.5%) with 43
types; high abundance of HPV-34, 53, 45, and 52; and a
high rate (~50%) of mixed infections [41]. Fonseca et al.
investigated the prevalence of HPV in isolated,
Fig. 2 HPV DNA detection by PCR amplification, capillary electrophoresis and dideoxy (Sanger) sequencing. a Gel image and electropherogram of
amplicon detection by high-resolution capillary electrophoresis. Representative samples #311, 312, 319, and 330 (HSIL) reveal 1 or 2 amplicons after using
consensus primers (GP-E6/E7 F/B) to amplify an E6/E7 segment with an expected fragment size of ~660 bp (range, 619-819 bp). Amplicon
size variability reflects sequence differences between HPV genotypes. In general, deep sequencing resolved a greater number of HPV genotypes
than capillary electrophoresis per sample. Sample #330 illustrates this with detection of 2 amplicons on electrophoresis, but 8 genotypes by deep se-
quencing. b Representative sample (#311) with a single HPV infection revealing 1 amplicon (699 bp peak on electropherogram) and clean sequencing
chromatogram. Representative sample (#319) with multiple HPV infections revealing 2 amplicons (619 and 656 bp peaks on electropherogram) and
“noisy” overlapping peaks on the chromatogram. AM, alignment marker; B, buffer; bp, base pair; M, molecular-weight marker
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indigenous Amazonian women of northern Brazil [15].
Among the 607 cytology samples, 3.3% were abnormal,
which included 7 cases of LSIL, 2 cases of HSIL, and 1
case of carcinoma. The overall HPV prevalence was
39.7% with 60 different genotypes and a high rate (45%)
of multiple infections. Only a limited number of HPVs
were found in HSIL and/or carcinoma (HPV-16 and 31)
and ASC-US/LSIL (HPV-16, 18, and 31). Finally, Meir-
ing and colleagues used deep sequencing to identify 16
HPV types in a South African HIV+ woman and demon-
strated that prevalent HPV types in HIV+ women are
undetectable by commercial tests that complicate sur-
veillance measures [16]. Taken together, these data dem-
onstrate that NGS reveals a diverse and prevalent
existence of mixed HPV infections in healthy females.
With progression of cytopathology, diversity diminishes
to a few virulent types, namely HPV-16 and other α-7,
-9 species as observed in our LSIL/HSIL samples and
Sjoeborg’s study using linear array genotyping [42].
Finally, for immunocompromised hosts, the HPV virome
may be more diverse and inclusive of less-virulent
genotypes.
In regards to age, our subjects with LSIL were younger
than those with HSIL. This finding is consistent with the
natural history of HPV infection with a characteristic
peak age of < 25 years for HPV infection/LSIL and 25–
35 years for HSIL [43]. Ironically, we found no difference
in the median age of subjects between those who had
and who did not have carcinogenic HPV genotypes by
NGS. A large population-based study conducted in New
Mexico showed similar age distributions as our sample
for both carcinogenic and low-risk HPV groups with the
peak age range being 21–24 years followed by a rapid
decline [44]. In fact, over 35% of women <21 years of
age and 32% between the ages of 21–24 years tested
positive for any carcinogenic HPV on cytology [44]. Col-
lectively, the disparate age distributions support the no-
tion that infection with a carcinogenic HPV occurs
predominantly in adolescence/early adulthood; whereas,
disease, i.e. HSIL develops in later adulthood.
The strength of this investigation lies in the clinical
specimens studied and sequencing method used. First,
we intentionally focused on precancerous cervical le-
sions, i.e. LSIL and HSIL because they have been under-
studied to date by deep sequencing. The remarkable
genotypic diversity and coinfection rates found in this
study have direct implications for vaccine development
and epitope selection, as well as post-immunization sur-
veillance for efficacy and emerging replacement-types
[45]. The recently FDA-approved 9-Valent HPV vaccine
(9vHPV) containing HPV 6, 11, 16, 18, 31, 33, 45, 52, and
58 virus-like particles (VLPs) is a significant improvement
over the quadrivalent vaccine. However, our study only
found 7/27 and 4/17 genotypes (~25%) in LSIL and HSIL,
Fig. 3 HPV genotype composition found in LSIL and HSIL samples. Deep sequencing of HPV E6/E7 amplicons derived from each LSIL or HSIL
sample identified 1 to 8 HPV genotypes and quantitated their composition (%) based on number of mapped reads to total mapped reads. The
top three dominant (highest proportion) genotypes found in LSIL were HPV-39, -16, and -35 [red, solid/hashed]. The carcinogenicity of LSIL dom-
inant genotypes were: carcinogenic 29/43 (67%, red); possibly carcinogenic 6/43 (14%, blue); and not classifiable/probably not carcinogenic 8/43
(19%, green). For HSIL, the dominant genotype was primarily HPV-16 (21/29, 72%); and the dominant genotypes were all carcinogenic 29/29
(100%, red). The HPV carcinogenicity is based on IARC’s classification of human carcinogens [8]. HSIL, high-grade squamous intraepithelial lesion;
IARC, International Agency for Research on Cancer; LSIL, low-grade squamous intraepithelial lesion; ID, identification
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respectively, covered by the 9vHPV epitopes. More im-
portantly, HPV-35 and -39 found highly prevalent in LSIL
and HSIL are not covered. Another additive concern
about vaccine ineffectiveness is the low vaccine uptake
and adherence rates in the U.S. [46, 47]. Consequently, ac-
tive, population-based surveillance is necessary to detect
potential redistribution of carcinogenic HPVs as a result
of under-achieved herd immunity [45, 48–50]. Second, we
used the most accurate NGS platform commercially avail-
able [12]. The least cumbersome DNA library preparation
was chosen to streamline the laboratory workflow. The
bioinformatics workflow created for HPV genotyping with
automatable steps systematized the computational ana-
lysis. The simple methods developed and tested in this
study may be adopted for studying HPV viromes at all
susceptible anatomical sites where surveillance is essential
[50]. Conversely, the high concordance rate found be-
tween deep and Sanger sequencing suggests that Sanger
remains a reliable method of detecting the dominant
genotype in single and mixed infections if decipherable by
BLAST®. In resource limited settings, Sanger sequencing
will remain salient. Although PCR/Sanger sequencing is
still the current reference standard for HPV clinical diag-
nostics, next-generation genotyping may soon gain
acceptance in the clinical realm as a new reference
method according to the 2015 FDA Draft Guidance on
HPV in vitro diagnostic devices [51]. Before adoption,
however, we opine that further investigation is required to
determine the threshold for variant detection (minimum
coverage) and variant filtering (percentage of reads in a
mixed population) for accurate next-generation HPV
genotyping. Two independent studies using admixtures of
Hepatitis C Virus (HCV) and influenza A plasmids sug-
gest that for accurate detection using Illumina’s sequen-
cing technology, the limit of variant detection and filtering
should be set ~100x and 0.5%, respectively [52, 53].
Cross-sectional studies, similarly to other observa-
tional studies are susceptible to errors due to chance
and bias. We acknowledge that the current study has
limitations. First, the potential for selection bias must be
considered. Our clinical samples were derived from a
South Texas military population represented largely by
Active Duty Members and dependents of the U.S. Army
and Air Force. The demographics, social, and sexual be-
havior of our population may not be representative of
other segments of the U.S. population. In general, HPV
prevalence should be interpreted in the context of eth-
nogeography. Second, atypical squamous and glandular
Fig. 4 HPV diversity, dominance and community structure between LSIL and HSIL. a Bar chart represents the relative abundance of HPV
genotypes found in LSIL and HSIL samples by deep sequencing. A total of 27 genotypes out of 43 samples were found in LSIL versus 17
genotypes out of 29 samples for HSIL with respective Shannon Wiener Indices, 3.01 and 2.28. The dominant (most abundant) genotype in LSIL
was HPV-39 (BPI, 0.15) versus HPV-16 for HSIL (BPI, 0.34). Species diversity analysis between LSIL and HSIL revealed loss of HPV diversity (*, p <0.001)
and domination by HPV-16 (*, p <0.001) in HSIL. b Principal component analysis (PCA) plots of HPV genotype composition in LSIL and HSIL sam-
ples. For LSIL and HSIL, HPV-16, 35, and 39 were identified as the three most influential genotypes within both HPV communities. Further species
dissimilarity analysis revealed greater average abundance of HPV-16 (68%) and -35 (13%) for HSIL versus HPV-39 (24%) for LSIL. BPI, Berger-Parker
Index; SWI, Shannon Wiener Index
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Fig. 6 Schematic diagram of evolving virus-host interactions on the cervix. After infection (left), virus-virus (middle) and virus-host (right)
interactions based on the principles of competitive exclusion and clonal evolution of cancer are illustrated [34–40]. Gause’s law of competitive
exclusion states that between two competing species, the species with the slightest advantage will ultimately dominate [34, 35]. The deep
sequencing results of this study corroborated this phenomenon in the virome with loss of diversity and gain of dominance by carcinogenic
HPVs as LSIL progressed to HSIL. Furthermore, the predominantly monotypic, carcinogenic virome observed in HSIL may be attributed to
monoclonal expansion of host cells with genome-integrated HPV DNA [36–38]. Carc, carcinogenic; HPV, Human papillomavirus; Not Class, not
classifiable; Poss Carc, possibly carcinogenic; Prob Not Carc, probably not carcinogenic
Fig. 5 Evolutionary relationships of HPV E6/E7 sequences derived from LSIL and HSIL samples. a Prototypical HPV genome based on the genetic
information of HPV-16. The contiguous E6 (477 bp) and E7 (297 bp) gene segment of each sample was the target used for sequencing, genotyping, and
phylogenetic analysis. b Phylogenetic tree of 28 representative E6/E7 nucleotide sequences (one from each genotype) revealed two distinct clades: high-
risk [black bracket] and low-risk [green bracket] that cluster respective species (α-5, 6, 7, 9, 11) and (α-3, 8, 10, 13, 15) within the α-genus. The evolutionary
distances between species also correlate with the level of IARC-defined carcinogenicity. This finding is consistent with phylogenetic trees constructed
traditionally from L1 ORF sequences [8]. The tree was inferred by the Neighbor-Joining method with the Maximum Composite Likelihood nucleotide
substitution model using MEGA6 [29]. The scale bar indicates nucleotide substitutions per site. The bootstrap values are displayed for the primary and
secondary nodes. The full tree is shown in Additional file 5: Figure S3. Carc, carcinogenic; Not Class, not classifiable; Poss Carc, possibly carcinogenic; Prob
Not Carc, probably not carcinogenic
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cells of undetermined significance (ASC-US and AGUS)
cytological categories were not studied. The overall fre-
quency of HPV+/ASC-US (1.1%) and HPV+/AGUS
(0.05%) is low among screening cytology samples; how-
ever, the 5-year risk of histologic HSIL and cancer are sig-
nificant, i.e. 18 and 45%, respectively [54]. Hence, to fill
this knowledge gap, we plan to investigate HPV metagen-
omes of uncommon cytological categories to further our
understanding of viral ecology, and we plan to establish
predictive models for cytological outcomes based on
metagenomics profiles. Third, we did not study LSIL/
HSIL samples with negative E6/E7 amplification results.
PCR non-detection (false-negative results) may be attrib-
uted to several variables, e.g. insufficient DNA template
quantity or quality and primer-target mismatch [11, 55].
To explore and compare the HPV metagenomes in E6/E7
amplicon-positive and -negative cytology, multiply-primed
rolling-circle amplification followed by deep sequencing
may offer a solution, in particular, to partially deleted or
poorly E6/E7-primed HPV genomes [13].
Conclusions
Deep sequencing has provided a powerful lens through
which to peer into viral communities and gain an under-
standing of a dynamic microcosm imperceptible with con-
ventional methods. The HPV diversity and community
characteristics found in LSIL and HSIL have provided vital
information relevant to cervical carcinogenesis, biomarker
discovery, vaccinology, and surveillance strategies. With
revolutionary advances in sequencing and computational
technologies, we are now able to decipher and interpret the
cryptic codes of an ancient virus in a manner reminiscent
of the Shakespearean metaphor, “In nature’s infinite book
of secrecy, a little I can read” [56].
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